Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Elisabetta Nobili"'
Autor:
Francesca Giunchi, Francesco Massari, Annalisa Altimari, Elisa Gruppioni, Elisabetta Nobili, Michelangelo Fiorentino, Andrea Ardizzoni
Publikováno v:
Diagnostics, Vol 10, Iss 12, p 1109 (2020)
The TMPRSS2:ERG fusion is considered prostate specific and has been rarely described in other tumors. We describe the case of a patient who developed lung and prostate cancers, both harboring the TMPRSS2:ERG fusion. The patient developed a cancer of
Externí odkaz:
https://doaj.org/article/7cbf5463908844fc81397ad101a5a549
Autor:
Elisabetta Nobili, Raffaele Pezzilli, Donatella Santini, Cristina Campidelli, Lucia Calculli, Riccardo Casadei, Guido Biasco
Publikováno v:
Case Reports in Gastroenterology, Vol 2, Iss 1, Pp 11-17 (2008)
We report a case of a male patient with autoimmune pancreatitis in whom biochemical examination revealed high plasma chromogranin A concentrations, histological demonstration of a small lymphocytic infiltrate and rapid decrease in size of the pancrea
Externí odkaz:
https://doaj.org/article/b5a917a2dd144649bc3232470bfc2e36
Autor:
Deborah Malvi, Elisabetta Nobili, Alessandro Federico, Stefano Brocchi, Giovanni Brandi, Barbara Lenzi, Daria Maria Filippini
Publikováno v:
Annals of Palliative Medicine. 10:8474-8478
Orbital metastases are an extremely rare finding in patients with hepatocarcinoma (HCC), especially as its first presentation. Therefore, the risk of misdiagnosis is high, as well as that of drastic delays of the therapeutic algorithm. Here we report
Autor:
Michelangelo Fiorentino, Elisabetta Nobili, Francesco Massari, Veronica Mollica, Riccardo Schiavina, Andrea Ardizzoni, Eugenio Brunocilla, Vincenzo Di Nunno
Publikováno v:
Clinical Genitourinary Cancer. 18:e83-e90
Background Several models are adopted in clinical practice to estimate prognosis of patients with metastatic renal cell carcinoma (mRCC); however, none of these models have evaluated patients treated by immune-checkpoint inhibitors. The aim of this s
Autor:
Giacomo Nuvola, Francesco Gelsomino, Monia Sisi, Andrea Ardizzoni, Elisa Andrini, Giuseppe Lamberti, Elisabetta Nobili, Barbara Lenzi, Alessandro Federico
Publikováno v:
Anti-cancer drugs. 32(7)
Until recently, platinum-based chemotherapy has represented the benchmark for the treatment of extensive disease small-cell lung cancer (ED-SCLC). ED-SCLC patients are often diagnosed with poor performance status (PS ≥2) and/or compromised organ fu
Autor:
Elisabetta Nobili, V. Di Nunno, A. Ardizzoni, Michelangelo Fiorentino, Eugenio Brunocilla, Riccardo Schiavina, F. Massari, Veronica Mollica
Publikováno v:
European Urology Supplements. 18:e3541-e3543
Autor:
Davide Campana, Alessandro Federico, Monia Sisi, Barbara Lenzi, Elisabetta Nobili, Giacomo Nuvola
Publikováno v:
Anti-cancer drugs. 31(10)
Hyperammonemic encephalopathy represents a rare adverse effect of several chemotherapeutic agents, occurring in about 0.7% of patients treated with fluoropyrimidines, and it is independent from dihydropyrimidine dehydrogenase deficiency. Instead, its
Autor:
Lidija Antunovic, Cristina Mosconi, Valentina Ambrosini, Alessandra Musto, Elisabetta Nobili, Lucia Zanoni, Rita Golfieri, Irene Bossert, Tiziano Graziani, Francesco Ceci, Andrea Ardizzoni, S. Zoboli, Stefano Fanti, Paolo Castellucci, Francesco Massari, Pietro Ghedini, Margarita Kirienko, Cristina Nanni, Barbara Melotti, Arturo Chiti
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 45:751-758
Aim: During our daily clinical practice using 11C-Choline PET/CT for restaging patients affected by relapsing prostate cancer (rPCa) we noticed an unusual but significant occurrence of hypodense hepatic lesions with a different tracer uptake. Thus, w
Autor:
Andrea Ardizzoni, Mollica, Beniamino Corcioni, Francesco Massari, Michelangelo Fiorentino, Rita Golfieri, Di Nunno, Elisabetta Nobili, Eugenio Brunocilla, Riccardo Schiavina
Publikováno v:
Anti-Cancer Drugs. 29:911-913
Nivolumab is an effective and tolerable treatment for metastatic renal cell carcinoma, showing longer median overall survival than everolimus and achieving a good percentage of objective response, stable disease, and prolonged responses. However, ver
Autor:
Rita Golfieri, Elisabetta Nobili, Michelangelo Fiorentino, Eugenio Brunocilla, Riccardo Schiavina, Beniamino Corcioni, Vincenzo Di Nunno, Francesco Massari, Veronica Mollica, Andrea Ardizzoni
In very few years, several treatments have significantly improved the prognosis of patients with metastatic renal cell carcinoma (RCC). Despite this, the clinical outcomes of specific subgroups of patients including those with central nervous metasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05989c608dd12893a6d31a31dbf579b0
http://hdl.handle.net/11585/635178
http://hdl.handle.net/11585/635178